IBAB Ion Beam Applications SA

IBA and ScandiDos form strategic alliance to increase access to safe radiotherapy

IBA and ScandiDos form strategic alliance to increase access to safe radiotherapy

Louvain-la-Neuve, Belgium, Stockholm, Sweden, Aug. 30, 2022 -  S.A. (IBAB.BR), the leader in particle accelerator technology and a leader in dosimetry quality assurance solutions, and ScandiDos A.B. (SDOS.ST), a technology leader in advanced Radiation Therapy Quality Assurance, announced today that they have formed a strategic alliance for radiation therapy dosimetry solutions. The collaboration will enable the two businesses to work together on product development, marketing and product distribution in selected markets, for patient quality assurance for radiotherapy. Specifics of the collaboration will be developed jointly by the parties in the coming months.

IBA Dosimetry and ScandiDos have secured this collaboration as part of their shared vision for a complete radiotherapy quality assurance solution. By combining the portfolios of both companies, IBA Dosimetry and ScandiDos can accomplish this vision, offering an increasingly extensive suite of products that provide a consistent solution for all aspects of radiotherapy quality assurance.

Under the terms of the agreement, IBA will purchase the full share issue (4,150,000 shares) made by ScandiDos on 30 August at a price of SEK 3.00, corresponding to an 8% premium on the average of the company’s last 12 month’s trading on the Stockholm stock exchange. Following the transaction IBA will hold 9.1% of ScandiDos A.B.’s share capital.

Jean-Marc Bothy, President of IBA Dosimetry, said: “This is an important milestone in our ongoing industry consolidation strategy. We are proud ScandiDos have chosen us as their partner for their expansion. For years, we have been impressed with the quality of the ScandiDos’ product portfolio in patient quality assurance and believe it is complementary to our rapidly expanding equipment and software offering. The combination of both companies’ product offerings will provide a unique level of quality, simplicity, and versatility to the medical physics community allowing them to deliver the full benefit of radiation therapy, with enhanced safety profiles to cancer patients everywhere.”

Gustaf Piehl, CEO of ScandiDos AB, added “Sharing a similar, long-term view of the quality assurance market for radiation therapy has been fundamental to building this alliance. By collaborating with IBA, a leading industry partner, ScandiDos will reach more customers on a global scale and contribute to making radiation treatment even safer than it is today. This strategic collaboration will also allow ScandiDos to maintain its independence to further develop the business while leveraging on IBA’s strong organizational capabilities.”

# # #

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

About ScandiDos

ScandiDos is an innovative forward-thinking company with groundbreaking software and hardware solutions for patient quality assurance in modern radiation therapy. Our Delta4 Family of products delivers a comprehensive QA solution, making the treatment process safe and efficient. We reinforce the confidence in radiotherapy clinics by providing professionals at the clinics with power and performance through independent QA.

The head office is in Uppsala Science Park, where product development is carried out. Sales are carried out by sales offices in the USA, Malaysia, and France, directly in the Nordic countries and through distributors in over 50 countries.

ScandiDos is listed on NASDAQ First North Stockholm with the ticker code SDOS. Certified adviser is Erik Penser Bank (08-463 83 00, ). Additional investor information can be found at . Product information can be found on 

For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer



Olivier Lechien

Corporate Communication Director



For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
30/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA launches CASSY®, a new compact radiochemistry module to enhance ef...

IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production   Louvain-La-Neuve, Belgium, 13 May 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announces the launch of CASSY®, a compact synthesizer designed to streamline radiopharmaceutical production processes. This new IBA solution is set to transform the way radiometals and radiotracers are produced. CASSY®, Compact Automated Scalable SYnthesis, enhanc...

 PRESS RELEASE

IBA lance CASSY®, un nouveau module compact de radiochimie pour amélio...

IBA lance CASSY®, un nouveau module compact de radiochimie pour améliorer l'efficacité de la production de radiopharmaceutiques Louvain-la-Neuve, Belgique, le 13 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce le lancement de CASSY®, un synthétiseur compact conçu pour rationaliser les processus de production de radiopharmaceutiques. Cette nouvelle solution IBA est destinée à transformer la manière dont les radiotraceurs et les radio...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Immediate Release – May 12th, 2025 Louvain-la-Neuve, Belgium, May 12th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 12 mai 2025 Louvain-la-Neuve, Belgique, 12 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décem...

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, May 12th, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on May 12th, 2025. In its notification, FMR LLC indicated that following an acquisition or disposal of s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch